Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

Tagrisso (osimertinib) - AstraZeneca

pemetrexed - Generic mfg.

carboplatin - Generic mfg.

YTS105 - BriSTAR Immunotech

cisplatin - Generic mfg.

Orpathys (savolitinib) - AstraZeneca, Hutchmed

https://meetings.asco.org/abstracts-presentations/246124/

Shun Lu; Jie Wang; Nong Yang; Dongqing Lv; Lijuan Chen; Lin Wu; XingYa Li; Longhua Sun; Yongfeng Yu; Bo Jin; Lin Yang; Yubiao Guo; Haipeng Xu; Tienan Yi; Aiping Zeng; Xiaorong Dong; Jianhua Chen; Ziping Wang; Tony Mok; Weiguo Su

Apr 23, 2025